PRR11

Across TCGA pan-cancer cohorts, PRR11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRR11 data layer compared with 32 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRR11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRR11 expression acts as an unfavorable survival marker, although some lineages such as MESO show a favorable association.

OV, PRAD, and SCLC are the cancer types where PRR11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.277	0.690	.013	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	OS	Median	All	0.274	0.711	.008	6	view →
LIHC	DFS	Median	All	0.097	0.543	.033	6	view →
MESO	DFS	Median	All	1.000	0.179	.041	3	view →
LUSC	OS	Median	All	0.405	0.679	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRR11–OV (OS)

Open the OV breakdown →